Myeloma Paper of the Day, June 8th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Patients with extramedullary myeloma have worse outcomes with idecabtagene vicleucel, with ORR 52% vs. 82% (without EMD), median PFS 5.3 vs. 11.1 months, median OS 14.8 months vs. 26.9 months.”
Source: Robert Orlowski/X
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Authors: Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar and Doris K. Hansen
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
